BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...
BioCardia (BCDA) announced completion of source data verification and freezing of primary outcomes data in the double-blind randomized placebo-controlled Phase 3 CardiAMP HF study of its autologous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results